Phio Pharmaceuticals Corp.
PHIO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001533040
In the last 90 days, Phio Pharmaceuticals Corp. insiders filed 5 open-market purchases and 0 sales; 24 institutions reported holding it in 13F filings for Q2 2026, worth $662.6K in total; no superinvestor holds it.
13F holders, Q1 2024
Institutional positions in Phio Pharmaceuticals Corp. as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 10
- −4 vs. Q4 2023
- Shares held
- 150.5K
- −356.4K (−70.3%) vs. Q4 2023
- Total value
- $106.1K
- −$282.6K (−72.7%) vs. Q4 2023
- New holders
- 1
- 2 more added
- Sold out
- 5
- 1 more reduced
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PHIO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 24 | $662.6K |
| Q1 2026 | 24 | $815.0K |
| Q4 2025 | 17 | $382.3K |
| Q3 2025 | 11 | $467.4K |
| Q2 2025 | 11 | $387.4K |
| Q1 2025 | 11 | $130.8K |
| Q4 2024 | 11 | $277.4K |
| Q3 2024 | 6 | $98.3K |
| Q2 2024 | 12 | $117.0K |
| Q1 2024 | 10 | $106.1K |
| Q4 2023 | 14 | $388.8K |
| Q3 2023 | 14 | $445.4K |
| Q2 2023 | 13 | $798.3K |
| Q1 2023 | 8 | $219.7K |
| Q4 2022 | 12 | $213.2K |
| Q3 2022 | 15 | $415.0K |
| Q2 2022 | 13 | $551.0K |
| Q1 2022 | 15 | $626.0K |
| Q4 2021 | 18 | $991.0K |
| Q3 2021 | 16 | $1.82M |
| Q2 2021 | 17 | $1.58M |
| Q1 2021 | 16 | $1.34M |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding Phio Pharmaceuticals Corp.; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Virtu Financial LLC | 30,912 | $21.0K | 0.00% | +11,868+62.3% | Added |
| Cetera Investment Advisers | 30,416 | $20.7K | 0.00% | +13,500+79.8% | Added |
| Bank of Montreal | 20,000 | $17.1K | 0.00% | 00.0% | Unchanged |
| Vanguard Group Inc | 24,380 | $16.6K | 0.00% | 00.0% | Unchanged |
| Bridgeway Capital Management, LLC | 23,486 | $16.0K | 0.00% | 00.0% | Unchanged |
| Cambridge Investment Research Advisors, Inc. | 14,233 | $10.0K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 5,697 | $3.87K | 0.00% | −16−0.3% | Reduced |
| UBS Group AG | 1,358 | $923 | 0.00% | +1,358 | New |
| Wells Fargo & Company | 19 | $13 | 0.00% | 00.0% | Unchanged |
| BlackRock Inc. | 1 | $1 | 0.00% | 00.0% | Unchanged |
| Sabby Management, LLC | 0 | $0 | 0.00% | −172,693−100.0% | Sold out |
| Anson Funds Management LP | 0 | $0 | 0.00% | −157,425−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −31,843−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −21,056−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −125−100.0% | Sold out |